Switch theme
Sign up to access all valuation multiples
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company’s segment consists of the development of clinical and preclinical product candidates for the development of the Company’s proprietary new therapies.
2017
4
LTM Revenue n/a
LTM EBITDA n/a
$4.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Acurx Pharmaceuticals has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Acurx Pharmaceuticals achieved revenue of n/a and an EBITDA of -$14.1M.
Acurx Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Acurx Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$14.6M | -$14.1M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$12.1M | -$14.6M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Acurx Pharmaceuticals's stock price is $0.
Acurx Pharmaceuticals has current market cap of $8.4M, and EV of $4.7M.
See Acurx Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.7M | $8.4M | XXX | XXX | XXX | XXX | $-0.84 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Acurx Pharmaceuticals has market cap of $8.4M and EV of $4.7M.
Acurx Pharmaceuticals's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Acurx Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Acurx Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.3x | XXX | XXX | XXX |
| P/E | -0.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAcurx Pharmaceuticals's NTM/LTM revenue growth is n/a
Acurx Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $3.5M for the same period.
Over next 12 months, Acurx Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Acurx Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Acurx Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -3% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $3.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Acurx Pharmaceuticals acquired XXX companies to date.
Last acquisition by Acurx Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Acurx Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Acurx Pharmaceuticals founded? | Acurx Pharmaceuticals was founded in 2017. |
| Where is Acurx Pharmaceuticals headquartered? | Acurx Pharmaceuticals is headquartered in United States of America. |
| How many employees does Acurx Pharmaceuticals have? | As of today, Acurx Pharmaceuticals has 4 employees. |
| Who is the CEO of Acurx Pharmaceuticals? | Acurx Pharmaceuticals's CEO is Mr. David P. Luci. |
| Is Acurx Pharmaceuticals publicy listed? | Yes, Acurx Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Acurx Pharmaceuticals? | Acurx Pharmaceuticals trades under ACXP ticker. |
| When did Acurx Pharmaceuticals go public? | Acurx Pharmaceuticals went public in 2021. |
| Who are competitors of Acurx Pharmaceuticals? | Similar companies to Acurx Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Acurx Pharmaceuticals? | Acurx Pharmaceuticals's current market cap is $8.4M |
| Is Acurx Pharmaceuticals profitable? | Yes, Acurx Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
